DHX37 Impacts Prognosis of Hepatocellular Carcinoma and Lung Adenocarcinoma through Immune Infiltration

Figure 3

DHX37 transcription in subgroups of patients with hepatocellular carcinoma and lung adenocarcinoma, stratified based on gender, disease stages, pathological grade, tumor status, and TP53 mutation (UALCAN). (a, g) Boxplot showing relative expression of DHX37 in normal and LIHC or LUAD samples. (b, h) Boxplot showing relative expression of DHX37 in normal individuals and LIHC or LUAD patients in stages 1, 2, 3, or 4. (c, i) Boxplot showing relative expression of DHX37 in normal individuals of either gender and male or female LIHC and LUAD patients. (e, k) Boxplot showing relative expression of DHX37 in normal individuals and LIHC or LUAD patients with lymph node metastasis. (f, l) Boxplot showing relative expression of DHX37 in normal individuals and LIHC or LUAD patients with mutant TP53 or nonmutant TP53. (d) Boxplot showing relative expression of DHX37 in normal individuals or LIHC patients with grade 1, 2, 3, or 4 tumors. (j) Boxplot showing relative expression of DHX37 in normal individuals or LUAD patients with or without smoking habits. , , , and .

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)